Engineered immune cells take on sarcoma in early trial

NCT ID NCT00902044

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether specially engineered immune cells (HER2-specific CAR T cells) can safely treat advanced sarcoma that has not responded to standard treatments. Up to 36 participants will receive an infusion of their own modified T cells, with some also getting chemotherapy beforehand to help the cells work better. The main goal is to find a safe dose and see if the therapy can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HER2-specific CAR T cells
What this could lead to: If it works, this could point toward a new treatment option for advanced sarcoma that has not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 36 participants, so it is too small to prove effectiveness. The treatment may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HER2-POSITIVE OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Texas Children's Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.